JP2016520050A5 - - Google Patents

Download PDF

Info

Publication number
JP2016520050A5
JP2016520050A5 JP2016512033A JP2016512033A JP2016520050A5 JP 2016520050 A5 JP2016520050 A5 JP 2016520050A5 JP 2016512033 A JP2016512033 A JP 2016512033A JP 2016512033 A JP2016512033 A JP 2016512033A JP 2016520050 A5 JP2016520050 A5 JP 2016520050A5
Authority
JP
Japan
Prior art keywords
composition
source
nutritional composition
acid
egcg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512033A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520050A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036297 external-priority patent/WO2014179526A1/en
Publication of JP2016520050A publication Critical patent/JP2016520050A/ja
Publication of JP2016520050A5 publication Critical patent/JP2016520050A5/ja
Pending legal-status Critical Current

Links

JP2016512033A 2013-05-01 2014-05-01 老化筋肉再生の増強方法 Pending JP2016520050A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361818237P 2013-05-01 2013-05-01
US61/818,237 2013-05-01
PCT/US2014/036297 WO2014179526A1 (en) 2013-05-01 2014-05-01 Methods for enhancing aged muscle regeneration

Publications (2)

Publication Number Publication Date
JP2016520050A JP2016520050A (ja) 2016-07-11
JP2016520050A5 true JP2016520050A5 (https=) 2017-06-01

Family

ID=50885012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016512033A Pending JP2016520050A (ja) 2013-05-01 2014-05-01 老化筋肉再生の増強方法

Country Status (11)

Country Link
US (1) US20160066610A1 (https=)
EP (1) EP2999359A1 (https=)
JP (1) JP2016520050A (https=)
CN (1) CN105188413A (https=)
BR (1) BR112015027563A2 (https=)
CA (1) CA2911471A1 (https=)
HK (1) HK1221609A1 (https=)
MX (1) MX2015015178A (https=)
PH (1) PH12015502319A1 (https=)
SG (1) SG11201508388YA (https=)
WO (1) WO2014179526A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015094772A1 (en) * 2013-12-18 2015-06-25 Abbott Laboratories Methods for increasing skeletal muscle protein synthesis using green tea extract
WO2016044272A1 (en) * 2014-09-16 2016-03-24 Abbott Laboratories Methods of preserving muscle strength during a period of muscle disuse by administering beta-hydroxy-beta-methylbutyrate and green tea extract
JP6664956B2 (ja) * 2015-02-27 2020-03-13 キリンホールディングス株式会社 筋分化促進組成物
ES2806684T3 (es) * 2015-09-16 2021-02-18 Abbott Lab Composición nutricional líquida, de larga duración y reducida en grasas
AU2017207910B2 (en) * 2016-01-13 2022-09-01 Metabolic Technologies, Inc. Compositions and methods of use of β-hydroxy-β-methylbutyrate (HMB) for joint stability
WO2017168006A1 (en) * 2016-04-01 2017-10-05 Dsm Ip Assets B.V. Beverages comprising stable granules of milled lutein
CN121177244A (zh) 2016-05-25 2025-12-23 技源集团股份有限公司 包含3-羟基-3-甲基丁酸的软凝胶胶囊剂
WO2018027070A1 (en) * 2016-08-04 2018-02-08 Seattle Gummy Company Compositions for athletic performance and methods of making and using thereof
WO2018027081A1 (en) * 2016-08-04 2018-02-08 Seattle Gummy Company Health management compositions and methods of making and using thereof
US20210368843A1 (en) * 2016-08-04 2021-12-02 Seattle Gummy Company Mineral compositions and methods of making and using thereof
US12370159B2 (en) 2016-10-21 2025-07-29 Metabolic Technologies, LLC Compositions and methods of use of beta-hydroxy-beta-methylbutyrate (HMB) and probiotics
WO2018075867A1 (en) * 2016-10-21 2018-04-26 Metabolic Technologies, Inc. COMPOSITIONS AND METHODS OF USE OF β-HYDROXY-β-METHYLBUTYRATE (HMB) AND PROBIOTICS
MX2019014595A (es) 2017-06-09 2020-02-05 Philip Morris Products Sa Articulo generador de aerosol que tiene un segmento de filtro fibroso.
US20190037904A1 (en) * 2017-08-04 2019-02-07 Sean R. Daly Food-based protein formulation
JP7368364B2 (ja) 2018-02-09 2023-10-24 トプソー・アクチエゼルスカベット α-ヒドロキシ化合物の製造方法およびその使用
WO2019246395A1 (en) * 2018-06-23 2019-12-26 Seattle Gummy Company Methods and compositions for reducing caffeine side effects
JP6541047B1 (ja) * 2018-10-18 2019-07-10 株式会社東洋新薬 経口組成物
JP2023517997A (ja) * 2020-03-10 2023-04-27 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 負荷誘発性筋肥大を増強するための新規栄養素
WO2021236440A1 (en) 2020-05-20 2021-11-25 Advanced Food Concepts, Inc. Athletic performance enhancement composition using menthol
CN112568444A (zh) * 2020-11-20 2021-03-30 格乐瑞(无锡)营养科技有限公司 一种缓解肌肉流失的组合物及其制备方法
WO2023190293A1 (ja) * 2022-03-30 2023-10-05 ニュートリー株式会社 とろみ状栄養組成物
WO2025030001A2 (en) * 2023-08-02 2025-02-06 Abbott Laboratories Methods and compositions for maintaining skeletal muscle mobility and/or mass, and/or for recovery of skeletal muscle strength
KR20250168792A (ko) * 2024-05-24 2025-12-02 주식회사 메타매스 프로바이오틱스 대사체를 유효성분으로 포함하는 근육질환의 예방 또는 치료용 조성물

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
RU2414897C2 (ru) * 2005-11-30 2011-03-27 Нестек С.А. Способы лечения потери мышечной массы
EP2025346B1 (en) * 2006-04-07 2016-08-10 Osaka University Muscle regeneration promoter
JP5507802B2 (ja) * 2006-08-10 2014-05-28 花王株式会社 筋肉老化抑制剤
JP2012533627A (ja) * 2009-07-20 2012-12-27 ネステク ソシエテ アノニム 機能状態の喪失を減弱する方法
CA2821312A1 (en) * 2010-12-27 2012-07-05 Abbott Laboratories Methods for facilitating muscle recovery after a period of disuse using beta-hydroxy-beta-methylbutyrate
WO2012097064A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for controlling blood glucose
WO2012097061A1 (en) * 2011-01-13 2012-07-19 Abbott Laboratories Nutritional compositions and methods for improving skeletal muscle protein metabolism

Similar Documents

Publication Publication Date Title
JP2016520050A5 (https=)
ES2731899T3 (es) Composición de vacuna nasal contra la gripe
RU2011129812A (ru) Профилактика и лечение ротавирусной диареи
WO2018084531A3 (ko) 골 질환, 비만 및 지질 관련 대사성 질환의 예방 또는 치료용 조성물
DE60336934D1 (de) Verwendung von igf-1-serumspiegel-erhöhenden indolessigsäure-derivaten zur herstellung eines arzneimittels zur behandlung von verschiedenen krankheiten
JP2015510888A5 (https=)
BRPI0806392A8 (pt) uso de aclidínio, aclidínio, método de tratamento ou prevenção e composição farmacêutica
JP2011225596A5 (https=)
BR0309837A (pt) Forma de administração trans-epicutânea para tratamento da sìndrome das pernas inquietas
RU2017134443A (ru) Способ лечения с применением традипитанта
CN111479580A (zh) 采用自噬诱发剂和高蛋白质的组合来诱发自噬的组合物和方法
JP2018523683A5 (https=)
JP2023025192A (ja) 筋肉の質及び/又は筋量のためのオレウロペイン又はクルクミンを使用する組成物及び方法
BR112012030641A2 (pt) métodos e composições para terapia farmacêutica oral
JP2017105861A5 (https=)
CN104257970B (zh) 一种外用跌打药膏
WO2006078424A3 (en) Polyherbal compositions and methods for treating viral infections
RU2013134133A (ru) Применение содержащих лактоферрин питательных композиций при поддержании устойчивости к заболеваниям и состояниям
MX2022013018A (es) Metodos para disminuir la atrofia muscular y/o promover la regeneracion muscular.
JP2019529569A5 (https=)
JP2016534062A5 (https=)
MX2010009640A (es) Uso de conjugados de interleucina-1 en el tratamiento de diabetes.
JP2014505679A5 (https=)
RU2013133998A (ru) Способы и композиции для предотвращения и лечения остеоартрита
WO2009019307A3 (en) Oral calcitonin compositions and applications thereof